Reactive oxygen species (ROS), the principal mediators of oxidative stress, induce responses such as apoptosis or permanent growth arrest/senescence in normal cells. Moreover, p53 activation itself contributes to ROS accumulation. Here we show that treatment of p53-null cancer cells with sublethal concentrations of ROS triggered an arrest with some morphological similarities to cellular senescence. Different from a classical senescent arrest in G 1 , the ROS-induced arrest was predominantly in the G 2 phase of the cell cycle, and its establishment depended at least in part on an intact Chk1-dependent checkpoint. Chk1 remained phosphorylated only during the repair of double strand DNA breaks, after which Chk1 was inactivated, the G 2 arrest was suppressed, and some cells recovered their ability to proliferate. Inhibition of Chk1 by an RNAi approach resulted in an increase in cell death in p53-null cells, showing that the Chk1-dependent G 2 checkpoint protected cells that lacked a functional p53 pathway from oxidative stress. It has been proposed that the induction of a senescent-like phenotype by antineoplastic agents can contribute therapeutic efficacy. Our results indicate that oxidative stress-induced growth arrest of p53-null tumor cells cannot be equated with effective therapy owing to its reversibility and supports the concept that targeting Chk1 may enhance the effects of DNAdamaging agents on cancer progression in such tumors.
Introduction
Reactive oxygen species (ROS) are generated by normal oxidative processes related to cell metabolism (Orr and Sohal, 1994; Nelms et al., 1998; Shiloh and Kastan, 2001) . They are produced initially by the reduction of singlet O 2 to superoxide anion and then H 2 O 2 that, if not eliminated, generates the highly reactive hydroxylfree radical that causes DNA damage (Riley, 1994; Finkel and Holbrook, 2000) . Increased levels of ROS can be induced by inflammatory responses, certain pathological processes and exposure to agents such as ionizing radiation (Bai and Cederbaum, 2003; Barzilai and Yamamoto, 2004) . Depending on the level of oxidative stress and the extent of the induced DNA damage, cell fate can vary from temporary arrest to death (see Davies (1999) and Barzilai and Yamamoto (2004) for a review). For instance, exposure to H 2 O 2 has been shown to induce apoptosis or necrosis depending on concentrations and cellular context (Caldini et al., 1998; Hampton and Orrenius, 1998; Davies, 1999; Sun et al., 2000) , whereas low concentrations of oxidants can force normal human fibroblasts to permanently arrest in a senescent-like state (Chen and Ames, 1994; Chen et al., 1995 Chen et al., , 1998 von Zglinicki et al., 1995; Caldini et al., 1998; Dumont et al., 2000; de Magalhaes et al., 2004) .
Replicative senescence occurs as a terminal differentiation state in which metabolically active cells are permanently arrested with distinctive morphological changes (Hayflick and Moorehead, 1961) and phenotypic markers (Dimri et al., 1995) , as a consequence of telomere shortening and/or dysfunction (Allsopp et al., 1992; Smith and Pereira-Smith, 1996; Campisi et al., 2001) . Senescence can also be triggered by oncogenes such as Ras (Serrano et al., 1997) or Raf (Zhu et al., 1998) , tumor suppressors such as p53 (Sugrue et al., 1997) and DNA-damaging agents (Chen et al., 1995; Robles and Adami, 1998) . Both ras and p53 can also cause ROS accumulation, which appears to play a role in these responses (Irani et al., 1997; Lee et al., 1999; Macip et al., 2003) .
When proliferating, if cells are subjected to DNA damage the cell cycle temporarily pauses either at G 1 , S or G 2 phase. Arrest at these checkpoints prevents DNA replication and mitosis in the presence of unrepaired DNA damage and presumably allows time for DNA repair to occur. The proportion of cells that arrest in G 1 , S or G 2 after damage depends on cell type, growth conditions, type of damage and the checkpoints operative in the cells. The G 1 checkpoint depends on activation of the tumor suppressor p53, which induces p21
Waf1/Cip1/Sdi1 expression and thereby inhibits cyclin-cdk complexes (Kastan et al., 1991; el-Deiry et al., 1993) . As p53 function is lost in most human cancers (Vogelstein, 1990; Greenblatt et al., 1994) , cancer cells often have a defective G 1 checkpoint response to DNA-damaging agents. Arrest at the G 2 checkpoint results primarily from activation of the Chk1 protein kinase, which maintains mitotic cyclin B/Cdc2 complexes in an inactive state (Kaufmann et al., 1995; Zhou and Elledge, 2000) . Peroxides such as H 2 O 2 or tert-butyl hydroperoxide (tBH) have been shown to induce both a p53-dependent G 1 checkpoint arrest, that can be attenuated by using antioxidants (Di Leonardo et al., 1994; Clopton and Saltman, 1995) , and a G 2 checkpoint response (Clopton and Saltman, 1995; Shackelford et al., 2001) .
The biochemical responses of normal cells to oxidative stress have been investigated in detail with respect to p53 functions. Oxidants have been shown to promote phosphorylation of p53 at serine 15 (S15), which can be blocked by antioxidants (Hammond et al., 2003) , and to induce an increase in p53 levels accompanied by elevation of its target gene p21 (Chen et al., 1998) . It is believed that the activation of the p53 pathway in response to oxidative damage contributes importantly to the resulting arrest or cell death responses observed (for revision see Barzilai and Yamamoto, 2004) . However, there have been few studies on responses to oxidative stress in cells lacking intact p53 functions (Hwang, 2002) . As cancer cells can be subjected to oxidative stress owing to the effects of many cancer therapeutics (Riley, 1994; Gewirtz, 1999; Renschler, 2004) , increased understanding of p53-independent responses to oxidative stress may be critical to developing more effective cancer therapies. It has been proposed that genotoxic stresses can induce senescence in p53-null as well as wild-type (wt) p53-containing cancer cells (for a review see Roninson, 2003) and that this response plays a role in the suppression of tumor growth by chemo and radiotherapy. However, recent studies have indicated that cancer cell lines without functional p53 pathways do not undergo senescence in response to a variety of chemotherapeutic agents (te Poele et al., 2002; Chiu et al., 2005; Roberson et al., 2005) . In the present study, we address this controversy by studying the arrest response of p53-null cancer cells to sublethal concentrations of ROS and the mechanisms involved.
Results
Oxidative stress can arrest p53 null cancer cells To test the effects of oxidative stress in cells lacking p53, we exposed p53-null EJ human bladder cancer cells to tBH, an organic hydroperoxide that has been shown to induce apoptosis in p53-expressing cells (Zamzami et al., 1998; Shackelford et al., 2001 ). EJ cells incubated with 100 mM tBH for 2 h did not undergo cell death but showed signs of growth arrest, associated with an elongated and flattened morphology resembling a permanent arrest/senescence phenotype ( Figure 1a) . However, treated EJ cells stained only weakly for the senescence-specific marker SA-b-gal (Dimri et al., 1995; Hara et al., 1996) when compared to EJ cells in which senescence was induced by tet-regulated p53 overexpression (Sugrue et al., 1997) . As shown in Figure 1b , addition of tBH induced a pronounced increase in intracellular oxidation, as measured by fluorescenceactivated cell sorter (FACS) analysis of dichlorodihydrofluorescein (DCF)-stained cells, and this increase was related to the concentration of added oxidant. Intracellular ROS subsequently fell, but remained elevated for several days before returning to basal levels (data not shown).
To determine whether the tBH-induced arrest in EJ cells was permanent, we analysed cell proliferation after exposure to tBH. When plates were seeded at low density, those treated with 100 mM tBH had no significant increase in cell number until day 10 ( Figure 1c, top panel) . This was reproduced in a colony formation assay, where cells treated with 100 mM tBH for 2 h showed no grossly observable colonies up to 14 days after oxidative stress (Figure 1d ). Nevertheless, by 21 days approximately 25% of treated cells formed detectable colonies, showing that some were able to escape this arrest. Moreover, cells plated at higher densities maintained the tBH-induced arrest for only about 4 days ( Figure 1c , lower panel). This indicates that the effects of oxidative stress on growth inhibition were enhanced at low cell density and is consistent with previous reports showing increased resistance of normal cells to different types of oxidants when cultured at high densities (Bakondi et al., 2003; Long et al., 2003) .
We further explored the tBH-induced arrest by staining for serine-10 phosphorylated histone H3, which is significantly upregulated in cells undergoing mitosis. The fraction of mitotic cells was strikingly inhibited after treatment, but began to increase after the fourth day post-tBH treatment (Figure 2a) , consistent with the results shown in Figure 1c (lower panel). We also checked the generation of ROS-induced DNA damage, specifically double strand breaks and generation of 8-oxoguanine, which are known to be induced by oxidative stress. Foci of phosphorylated histone gH2A-X, a marker that accumulates at sites of DNA double strand breaks (Fernandez-Capetillo et al., 2004; Foster and Downs, 2005) , were apparent as early as 2 h after treatment (data not shown), peaked at 8 h and were no longer detectable by 24 h (Figure 2c ). In contrast, positive staining for 8-oxoguanine, a specific marker of oxidative DNA damage, was observed within 2 h and did not return to basal levels until around the eighth day ( Figure 2b ). All these findings together indicate that although oxidative damage strongly inhibited the proliferation of p53-null cancer cells, eventually a portion of cells recovered cycling potential.
A G 2 checkpoint is activated in response to oxidants in the absence of p53 To better characterize the difference between the prolonged but reversible tBH-induced arrest in p53-null cells and senescence, we examined the cell cycle profile of EJ cells 2 h to 12 days after treatment. As shown in Figure 3a , following a delayed transition through S phase, accumulation of cells in G 2 began around 12 h after exposure to tBH and increased progressively. The elevated proportion of G 2 arrested cells was maintained for at least 2 days after treatment, consistent with the lack of cells in mitosis during this time (see Figure 2a) . By the third day, the profile resembled that of untreated cells, although some cellular debris lacking significant levels of DNA was also detected at this time, implying the loss of cellular integrity in a subpopulation of cells. A similar G 2 arrest could also be seen after tBH treatment of other p53 inactivated cancer cells, including DLD-1, HeLa and SAOS-2 ( Figure 3b ). Of note, the concentrations of tBH needed to induce G 2 arrest in the absence of apoptosis varied among cell lines, presumably owing to their different sensitivities to oxidative stress. We compared these results to the response of wt p53-containing human diploid fibroblasts (HDFs) treated for 2 h with 100 mM. At 48 h after treatment, HDFs were arrested predominantly in G 1 , with a G 1 increase Hundred cells were plated in control and tBH plates. tert-butyl hydroperoxide plates were treated with 100 mM tBH for 2 h after cells were attached. Cells were allowed to grow for 14-21 days before being stained with Giemsa.
Response of p53-null cancer cells to oxidative stress S Macip et al from 59.3 to 76.7% and a concomitant S-phase reduction from 25.6 to 6.7% ( Figure 3b ). This is consistent with the fact that wt p53-containing cells arrest primarily in the G 1 phase of the cell cycle after low levels of DNA damage (Chen et al., 1998) . When concentrations of tBH were elevated, there was an increase in apoptosis in the HDFs (Figure 3b , lower panel), associated with an increase in intracellular oxidation, as measured by glutathione depletion.
We next compared the effects of tBH on HCT116, a wt p53 colon cancer cell line, and HCT116p53 À/À in which both alleles of p53 were inactivated by somatic gene targeting (Zhang et al., 2000) . Treatment of HCT116 p53 À/À cells with 100 mM tBH induced a G 2 arrest ( Figure 3c ) whereas wt HCT116 cells showed a pronounced increase in cell death under the same conditions. This is consistent with previous studies indicating that p53 cooperates with oxidative stress to induce apoptosis (Macip et al., 2003) . We also compared the effects of p53 status on the response to oxidative stress in wt and p53 À/À primary mouse embryo fibroblasts (MEFs) (Figure 3d ). Whereas p53 À/À MEFs arrested in G 2 in response to tBH treatment, cell death was predominantly induced in wt MEFs under the same conditions. Induction of apoptosis was confirmed by Annexin V/PI staining (data not shown). Together, these results demonstrate that sublethal oxidative stress in cells lacking p53 activates a prolonged but reversible G 2 checkpoint, whereas the presence of p53 favors G 1 arrest/senescence and/or apoptosis in response to the same stimulus.
Chk1 is preferentially activated after oxidative damage in the absence of p53 It has been reported that in the absence of a functional p53 pathway, a G 2 checkpoint involving Chk1 is responsible for cell cycle arrest after genotoxic stress (Zhou and Elledge, 2000) . Chk1 is a serine/threonine kinase that controls cell cycle arrest in G 2 /M when activated by phosphorylation on serines 317 and 345 (S317 and S345, respectively) following DNA damage (Liu et al., 2000; Koniaras et al., 2001; Zhao et al., 2002) . To test the possible role of Chk1 in the tBHinduced G 2 arrest of p53-null cancer cells, we first measured the levels of activated Chk1 following tBH exposure in EJ cells. Of note, Chk1 was phosphorylated at S317 as early as 2 h after treatment and remained detectably activated for 24 h (Figure 4a ). Similar results were obtained with an antibody against Chk1 phosphorylated at S345 (data not shown). Chk2, a functionally distinct kinase that is also activated by Response of p53-null cancer cells to oxidative stress S Macip et al phosphorylation in response to genotoxic stress (Bartek et al., 2001; Bartek and Lukas, 2003) , showed an increased level of phosphorylation, which was initiated later and persisted longer than Chk1 activation in tBHtreated cells (Figure 4a ). However, recent reports have indicated that Chk2 does not play a role in cell cycle checkpoints (Takai et al., 2002; Jallepalli et al., 2003; Ho et al., 2005; de Vries et al., 2005) and thus is unlikely to be involved in the arrest following oxidative stress. We next studied the effects of the presence or absence of p53 on tBH-induced activation of Chk1 using EJ cells with tetracycline (tet)-regulatable p53 expression (Sugrue et al., 1997). Chk1 was phosphorylated in EJ cells in the absence of p53 induction after treatment with 100 or 300 mM tBH, similarly to levels observed in HeLa cells exposed to 10Gy g-radiation as a control (Figure 4b ). Under conditions of p53 upregulation by tet removal before tBH treatment, Chk1 phosphorylation was detectable only at the highest tBH concentration (300 mM), suggesting its preferential activation in the p53-null EJ cells. As expected, p53 target genes, p21 and Bax, were upregulated only in p53-expressing EJ cells, showing that the p53 pathway was functional. Cell cycle profiles confirmed a G 2 arrest in the absence of p53 and increased apoptosis in p53-expressing EJ cells was observed, as previously reported (Macip et al., 2003) (Figure 4c ). Preferential activation of Chk1 was also seen in HCT116 p53
À/À cells as compared to wt p53 HCT116 cells treated with the same concentration of tBH (100 mM) (Figure 4d ). These results strengthen the conclusion that Chk1 is preferentially activated in response to oxidative stress in p53-null cancer cells.
Chk1 activation protects p53-null cells at the G 2 checkpoint in response to oxidative damage To test whether Chk1 was involved in the induction of the G 2 arrest in tBH-treated EJ cells, we generated Chk1 þ / þ p53 À/À or mouse embryo fibroblasts, untreated or 24 h after being treated with 100 mM tBH for 2 h. Cells in sub-G 1 fraction (apoptotic), from front to back, are 9.53, 76.17, 4.96 and 3.92% of total, respectively. Cells in G 2 /M fractions are 35.54, 76.17, 4.96 and 3.92%.
Response of p53-null cancer cells to oxidative stress S Macip et al interfering shRNA. As shown in Figure 5a , transfection of EJ cells with the Chk1 shRNA constructs markedly abrogated endogenous Chk1 expression, as evidenced by both Western blotting and immunofluorescence, in which Chk1 showed a pan-nuclear localization. When we performed a colony formation assay with tBHtreated p53-null EJ cells transfected with Chk1 shRNA, the late appearing colonies were significantly reduced in number compared to those observed in the same cells possessing normal levels of Chk1 (Figure 5b ), suggesting that lack of a functional Chk1 checkpoint in these cells increased cell death after oxidative stress.
To test this possibility, we transfected EJ cells with Chk1 shRNA and green fluorescent protein (GFP) either in the presence or absence of p53 induction, and measured cell cycle profiles of only the GFP-expressing cells. As shown in Figure 5c , p53 expression markedly inhibited DNA synthesis, but Chk1 shRNA had no detectable effect on the cell cycle profiles of either uninduced or p53 expressing EJ cells. At 24 h after tBH treatment of uninduced EJ cells, the depletion of Chk1 before treatment impaired the accumulation in the G 2 phase of the cell cycle (Figure 5c ), confirming the importance of Chk1 in the induction of G 2 arrest after oxidative damage in these cells. Moreover, the SubG 1 population increased significantly after exposure to tBH in the cells transfected with Chk1 shRNA (Figure 5c ). Owing to the nature of this assay, the actual percentage of the SubG 1 population is likely to be underestimated, as cell death leads to a significant reduction of GFP fluorescence owing to loss of cell integrity. EJ cells expressing p53 showed a much higher SubG 1 fraction after tBH treatment (Figure 5c ), consistent with previous findings (Macip et al., 2003) . Owing to the large amount of cell death in these tBH-treated cells, it was not possible to evaluate whether Chk1 inhibition had any additional effect. These results together imply that the combined lack of ability to arrest at either G 1 or G 2 checkpoints in response to oxidative stress induced a higher susceptibility to cell death, and is consistent with previous results (Koniaras et al., 2001) showing that Chk1 inhibition renders p53-null cells more sensitive to genotoxic stress (for a review, see Zhou and Bartek, 2004) . Taken together, these data demonstrate that in p53-null cancer cells the response to oxidative stress involves a Chk1 triggered G 2 checkpoint, which protects them by inducing a prolonged but reversible G 2 cell cycle arrest.
Discussion
The response of normal cells to oxidative stress varies from transient or permanent arrest to cell death by apoptosis or necrosis, depending on the amount of ROS generated (Davies, 1999 ; Barzilai and Yamamoto, À/À cells 12 h after being treated with 100 mM tBH for 2 h.
Response of p53-null cancer cells to oxidative stress S Macip et al 2004). We previously reported that tet-regulated p53 expression can induce permanent growth arrest/senescence in p53 null cancer cells associated with accumulation of ROS (Macip et al., 2003) . Moreover, these studies implicated ROS accumulation as contributing to the senescent phenotype. The response of p53-null cells to oxidants has not been as well characterized (Hwang, 2002; Barzilai and Yamamoto, 2004) . This is especially important in the context of cancer therapies directed at cells that lack a functional p53 pathway (Levine, 1997) , as ionizing radiation as well as some chemotherapeutics exert their antineoplastic functions partly through an increase in intracellular oxidants (Riley, 1994; Gewirtz, 1999) . Our present study established that the response of p53-null cancer cells to an exogenous source of oxidative stress has some phenotypic similarities to a senescencelike arrest, but instead involves activation of a G 2 checkpoint associated with increased Chk1 activation, from which a fraction of cells eventually escaped. Previous studies have shown that a Chk1-dependent G 2 checkpoint is activated in response to genotoxic stress in the absence of p53 (Koniaras et al., 2001; . Our studies extend these findings and establish that the initial delayed S-phase and subsequent activation of a G 2 checkpoint in p53-null cancer cells in response to oxidative stress is Chk1-mediated. Several lines of evidence support this conclusion. Chk1 activation, as detected by Chk1 phosphorylation, occurred rapidly following tBH exposure and persisted for around 24 h. Moreover, the kinetics of Chk1 activation correlated well with the time course of double-stranded DNA breaks (DSBs) as measured by gH2AX foci, and Chk1 is known to be activated in response to double stranded breaks (Latif et al., 2004) . To our knowledge, this is the first demonstration of Chk1 activation kinetics from checkpoint initiation to recovery in human cells, and differs from that described in yeast systems where Chk1 persists in an activated state into the next cell cycle (Latif et al., 2004; . Finally, the initial tBHinduced G 2 arrest observed in p53-null cells was significantly impaired by a Chk1 shRNA. (c) Representative cell cycle profiles of propidium iodide-stained EJ cells, expressing or not ectopic p53, treated with 100 mM tert-butyl hydroperoxide (tBH) for 2 h. Cells were cotransfected with GFP and Chk1 shRNA, or GFP and control shRNA (luciferase) 48 h before being exposed to tBH. Cells were stained 24 h after tBH treatment and subjected to fluorescene-activated cell sorter. Profiles of GFP-positive cells are shown. Green fluorescent protein-negative profiles were identical to luciferase shRNA profiles (not shown). Numbers indicate percentages of cells in each phase of the cell cycle.
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Our studies further indicate that the effects of oxidative stress on p53-null cancer cell proliferation cannot be explained solely by DSBs and Chk1 activation, as cell cycle profiles and proliferation were not completely normalized until oxidative damage to DNA became undetectable, long after DSBs were repaired. The incorporation of 8-oxoguanine into DNA, which leads to mutations owing to G to T transitions, was not significantly reduced until the third or fourth day, whereas DSBs were repaired within 24 h. Therefore, the initial phase of G 2 -arrest may be triggered by different kinds of major oxidative DNA damage, which likely require complete repair before proliferation resumes. We also observed a delayed onset and longer persistence of Chk2 activation. However, recent evidence showed that cells lacking Chk2 are checkpoint proficient (Takai et al., 2002; Jallepalli et al., 2003; de Vries et al., 2005; Ho et al., 2005) , suggesting that Chk2 activation does not play a role in the ROS-induced G 2 arrest in p53 null cells.
After the Chk1-mediated arrest in G 2 was completed, p53-null tumor cells slowly reinitiated cycling activities and attempted to enter mitosis, but only a portion was successful. The rest underwent a p53-independent form of cell death, presumably necrosis or mitotic crisis. This is consistent with the fact that the inability to arrest in either G 1 or G 2 has been described to drive cells with damaged DNA into mitotic catastrophe (Roninson et al., 2001; Castedo et al., 2004) . The reasons for this lack of recovery remain to be elucidated but may relate to incomplete repair of double strand breaks, inappropriate repair leading to chromosome aberrations, or to oxidative damage to proteins and lipids, which we did not directly measure but is also known to occur after exposure to oxidants (Dean et al., 1997; Davies, 1999) . A similar G 2 arrest in p53-null cancer cells after genotoxic stress has been recently shown in lung cancer cells after treatment with the type II topoisomerase inhibitor etoposide (Chiu et al., 2005) .
The senescent response in wt p53-containing cells is known to downregulate genes involved in the G 2 /M checkpoints (Mason et al., 2004) . In the present study, we observed that Chk1 phosphorylation in EJ and HCT116 cells after oxidative stress was decreased in the presence of induced p53. Chk1 and p53 are activated by the same upstream kinases, ATM and ATR (Bakkenist and Kastan, 2004) . This raises the possibility that the inhibition of Chk1 phosphorylation in the presence of intact p53 in EJ cells may involve substrate competition for these kinases. Alternatively, Chk1 may not be efficiently activated before origin firing in S-phase, and induction of p21 by p53 would delay cell cycle progression into S-phase. This hypothesis is supported by the observations of low-activated Chk1 expression in G 1 (Kaneko et al., 1999) , and that single strand DNA needs to be generated during DNA repair or replication arrest to aid in ATR-mediated Chk1 activation (O'Connell and Cimprich, 2005) . Further studies will be required to elucidate this crosstalk between the p53 and Chk1 responses.
It has been shown that inhibiting the ability of p53-null cells to arrest in G 2 increases sensitivity to chemotherapeutic agents (Jackson et al., 2000; Curman et al., 2001; Koniaras et al., 2001) , and Chk1 inhibition is currently being tested as an adjuvant in antitumor therapies to specifically favor death of tumor cells lacking p53 function (Garber, 2005) . Although we confirmed that Chk1 knockdown increased cell death in response to oxidative stress, this increase did not reach the level observed in the same cells expressing wt p53. Moreover, the senescence-like arrest induced by oxidative stress was reversible, in that some cells eventually escaped in the presence or absence of Chk1 knockdown. Recent studies have reported that some chemotherapeutic agents, such as ionizing radiation, doxorubicin, etoposide and cisplatin (Chang et al., 1999) , can induce a senescence-like arrest in p53-null cancer cells, which can also be observed in vivo (for a review see Roninson, 2003) . Further, it has been proposed that this senescence response implies permanent growth arrest, which like apoptosis can promote the equivalent of tumor cell death in response to cancer therapy (Roninson, 2003) . Our present findings imply that oxidative stress-induced senescence-like response in p53-null tumor cells cannot necessarily be equated with effective therapy owing to its reversible nature. This is consistent with a recent report showing that p53-null cancer cells can escape a senescence-like state induced by different chemotherapeutic agents (Roberson et al., 2005) . Thus, the presence of senescent-like cells in treated p53-null tumors could, in fact, be a negative prognostic factor, as it would suggest protection from therapy-induced genotoxic stress by a Chk1-dependent arrest.
Materials and methods
Cell culture EJ, DLD-1, HeLa, SAOS-2, 501T HDFs and MEFs were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and penicillin-streptomycin (50 U/ml). EJ cells with a tetracycline (tet)-regulated expression system (Sugrue et al., 1997; Fang et al., 1999) were maintained in DMEM supplemented with 10% FBS, penicillin-streptomycin (50 U/ml), hygromycin (100 mg/ml) and geneticin (750 mg/ml), plus 1 mg/ml tet to repress expression of p53. Fresh medium with tet was added every 3 days. To induce gene expression, cells were washed three times with phosphate-buffered saline (PBS) and seeded in medium in the absence of tet. Cells were treated by adding to the medium tBH (Sigma, MO, USA) for the specified time. If chemical was to be removed, cells were washed twice with PBS before adding fresh medium.
Senescence-associated b-galactosidase (SA-b-gal) staining Cells were washed in PBS and fixed with 2% formaldehyde/ 0.2% glutaraldehyde in PBS for 5 min at room temperature. Plates were stained as described (Dimri et al., 1995) .
Fluorescene-activated cell sorter analysis Fluorescent-stained cells were transferred to polystyrene tubes with cell-strainer caps (Falcon, NJ, USA) and subjected to FACS (Beckton Dickinson FACScan, NJ, USA) using Cell
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Measurement of intracellular oxidation
Cells were incubated with 5 mg/ml of DCF (Molecular Probes, Invitrogen, CA, USA) for 30 min at 371C, then washed with PBS, trypsinized and collected in 1 ml of PBS, followed by FACS analysis. Values of mean fluorescence intensity were used to plot graphics.
Colorimetric assay for glutathione A colorimetric assay to determine intracellular glutathione concentrations (Oxford Biomedical Research, MI, USA) was used as described by the manufacturer.
Cell cycle analysis Cells were stained with propidium iodide (PI), using the CycleTEST Plus DNA reagent kit (Beckton Dickinson), following the instructions provided by manufacturer, and then subjected to FACS analysis. Alternatively, GFP-expressing cells were fixed with 0.5% formaldehyde and 90% methanol to preserve GFP fluorescence, then incubated with RNAse A (40 mg/ml) and PI (20 mg/ml) for 60 min before FACS analysis.
Annexin/Propidium iodide fluorescent staining Cells were washed with PBS, trypsinized and then incubated with Annexin V and PI using the Anenxin-V-Fluos Staining kit (Boehringer Manheim, IN, USA), as reported (Aubry et al., 1999; Bartkowiak et al., 1999) , followed by FACS analysis. Cells negative for the two dyes were considered live cells.
Histone H3 staining Cells were fixed with 0.5% formaldehyde, then stained with an antibody against phospho-S10-histone H3 (Cell Signaling Technology, MA, USA, 1:500), in the presence of RNAse A (0.1 mg/ml), followed by fluorescein isothiocyanate-conjugated second antibody (Jackson Immunoresearch, Philadelphia, USA) . Costaining with PI was followed by FACS analysis.
Quantitation of oxidative damage to DNA EJ cells treated with tBH as described were stained with OxyDNA Assay Kit (Calbiochem, CA, USA) following the manufacturer's instructions to detect presence of 8-oxoguanine.
Detection of DNA phospho-H2AX (S139) As a marker for DSBs, cells were stained for Phospho-H2AX (S139). EJ cells grown on coverslips were treated as described, then methanol fixed for 20 min at À201C. Cells were incubated briefly in cold acetone 100%, then washed three times with PBS. Coverslips were blocked with 5% goat serum for 10 min and incubated with primary antibody (Phospho-H2AX S139, Upstate, VA, USA) for 1 h at room temperature, washed with PBS and incubated with 1:500 secondary antibody (Alexa 488, Molecular Probes) for 1 h. After washing with PBS, cells were counterstained with 4,6,diamidino-2-phenylindole (DAPI), mounted on glass slides and analysed with a Nikon Eclipse E800 microscope.
Immunoblot analysis
Cells cultured in the presence or absence of tet were washed twice with PBS and lysed in 10 mM Tris pH 7.4, 30 mM Na 4 P 2 O 7 , 150 mM NaCl, 50 mM NaF, 1% NP-40, 0.5 mM Na 3 VO 4 , 10 mM b-glycophosphonate, 0.1% SDS and 1 mg/ml protease inhibitor cocktail (Sigma). Lysates were cleared by centrifugation at 14 000 r.p.m. for 20 min at 41C. Protein concentrations were then determined using the BioRad Dc Protein Assay. 100 mg of total cell protein per sample was subjected to 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to Protean nitrocellulose filter (Schleicher & Schuell, NH, USA). An enhanced chemiluminescence detection system (Amersham, NJ, USA) was used. p53 was detected with the 1801 monoclonal antibody, phospho-p53 (S15) with the polyclonal antibody from Cell Signaling Technology, p21 with the Ab-1 monoclonal antibody (Oncogene Science, CA, USA) and BAX with the N-20 polyclonal antibody (Santa Cruz, CA, USA). Phospho-Chk1 (Serine 317 or 345) and Chk2 (Threonine 68) were detected using phospho-specific antibodies (Cell Signaling Technology). Total Chk1 and Chk2 were detected using monoclonal antibodies (G4, Santa Cruz and GeneTex, TX, USA respectively).
Depletion of Chk1
In order to suppress Chk1 expression by shRNA interference, two hairpins representing different human Chk1 coding region sequences were cloned into pSUPER plasmid. The constructs made contained oligonucleotides corresponding to nucleotides 127-147 (pSUPER1), and 476-496 (pSUPER2) of the human Chk1 coding region. EJ cells were transfected with equal amounts (10 mg) of pSUPER1, pSUPER2 and pEGFP-C1 using Lipofectamine 2000 (Invitrogen, CA, USA) as described by the manufacturer. Cells were analysed by Western blot or FACS 48 h after transfection. Cells cotransfected with GFP and shRNA were gated and analysed for cell cycle profiles as above. A non-relevant shRNA (against luciferase) was used as a negative control in all transfection experiments.
Immunostaining for Chk1
At 48 h after transfection, EJ cells were fixed with 4% formaldehyde in PBS for 10 min at room temperature. Cells were then permeabilized with 0.2% Triton X100 for 5 min at room temperature and blocked with 5% goat serum for 10 min at room temperature. Next, coverslips were incubated with the primary antibody (anti-Chk1, Stressgen, CA, USA, monoclonal 1:100) for 1 h at room temperature, washed with PBS and incubated with 1:500 secondary antibody (Alexa 568, Molecular probes) for 1 h at room temperature. After washing with PBS, cells were counterstained with DAPI, mounted on glass slides and analysed with a Nikon Eclipse E800 microscope.
